US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

8.40

-0.5400-6.04%

Post-market: 8.500.1000+1.19%19:16 EDT

Volume:1.39M

Turnover:12.03M

Market Cap:262.84M

PE:-2.95

High:9.25

Open:8.90

Low:8.40

Close:8.94

52wk High:50.40

52wk Low:8.40

Shares:31.29M

Float Shares:15.69M

Volume Ratio:0.67

T/O Rate:8.88%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8500

EPS(LYR):-2.8503

ROE:-33.63%

ROA:-21.86%

PB:0.92

PE(LYR):-2.95

Loading ...

Overview Company News Filings

Citi opens ‘upside 90-day catalyst watch’ on Travere Therapeutics

PYC Therapeutics Advances ADOA Drug PYC-001 With New Clinical Data and Ongoing Trial

Percheron Therapeutics Launches Discounted Entitlement Offer, Excludes Overseas Holders

Outlook Therapeutics Announces Proposed Public Offering

Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis

Context Therapeutics FY Net Loss Narrows

MT Newswires Live

Context Therapeutics Highlights Evolving T Cell Engager Pipeline

Intensity Therapeutics Expands ATM Equity Offering Capacity

Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings

Benzinga_recent_news

Top News Today/Canada: Bank of Canada to Lose Two Members of Rate-Setting Governing Council

Small U.S. Stocks Move Upward; Damora Therapeutics Top Leaders

Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate

Press Release: Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Quince Therapeutics options imply 68.7% move in share price post-earnings

Pelthos Therapeutics Inc trading resumes

Qyuns Therapeutics Invests RMB100 Million in Low-Risk Wealth Management Product

Tempest Therapeutics Announces Private Placement Financing Agreement

Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

Damora Therapeutics appoints Jennifer Jarrett as CEO

Press Release: Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LENZ/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":8.4,"timestamp":1774641600000,"preClose":8.94,"halted":0,"volume":1393631,"hourTrading":{"tag":"盘后","latestPrice":8.5,"preClose":8.4,"latestTime":"19:16 EDT","volume":25181,"amount":211529.72,"timestamp":1774653413550,"change":0.1,"changeRate":0.011905,"amplitude":0.011905},"delay":0,"changeRate":-0.060402684563758295,"floatShares":15692500,"shares":31289969,"eps":-2.85,"marketStatus":"Market Closed","change":-0.54,"latestTime":"03-27 16:00:00 EDT","open":8.9,"high":9.25,"low":8.395,"amount":12026989.540177,"amplitude":0.095638,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.85,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":8.94,"preHourTrading":{"tag":"盘前","latestPrice":8.95,"preClose":8.94,"latestTime":"09:25 EDT","volume":2891,"amount":25925.149467,"timestamp":1774617913255,"change":0.01,"changeRate":0.001119,"amplitude":0.016779},"postHourTrading":{"tag":"盘后","latestPrice":8.5,"preClose":8.4,"latestTime":"19:16 EDT","volume":25181,"amount":211529.72,"timestamp":1774653413550,"change":0.1,"changeRate":0.011905,"amplitude":0.011905},"volumeRatio":0.670644,"impliedVol":1.3191,"impliedVolPercentile":0.9877},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":15692500,"roa":"-21.86%","roe":"-33.63%","lyrEps":-2.850329,"volumeRatio":0.670644,"shares":31289969,"dividePrice":0,"high":9.25,"amplitude":0.095638,"preClose":8.94,"low":8.395,"week52Low":8.395,"pbRate":"0.92","psRate":"13.77","week52High":50.4,"institutionHeld":0,"latestPrice":8.4,"eps":-2.85,"divideRate":0,"volume":1393631,"delay":0,"ttmEps":-2.85,"open":8.9,"prevYearClose":16,"prevWeekClose":10.48,"prevMonthClose":13.49,"prevQuarterClose":16,"fiveDayClose":10.48,"twentyDayClose":13.49,"sixtyDayClose":16.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59},{"market":"US","date":"2025-07-30","symbol":"LENZ","fiscalQuarterEnding":"2025/06","expectedEps":-0.58,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753848000000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.4286,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5714,"analysts":7,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-03-27","current":-2.947368,"percent":1,"low":-26.69966,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"high":-3.413108,"avg":-12.467749,"sd":5.207963,"marketCap":280308282},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282}],"updateTime":1774706646997},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621334033","title":"Citi opens ‘upside 90-day catalyst watch’ on Travere Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2621334033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621334033?lang=en_us&edition=fundamental","pubTime":"2026-03-24 07:25","pubTimestamp":1774308338,"startTime":"0","endTime":"0","summary":"Citi added an “upside 90-day catalyst watch” on shares of Travere Therapeutics (TVTX) while keeping a Buy rating on the name with a $48 price targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citi-opens-upside-90-day-catalyst-watch-on-travere-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citi-opens-upside-90-day-catalyst-watch-on-travere-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","TVTX","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2621080189","title":"PYC Therapeutics Advances ADOA Drug PYC-001 With New Clinical Data and Ongoing Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621080189","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621080189?lang=en_us&edition=fundamental","pubTime":"2026-03-24 06:17","pubTimestamp":1774304270,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited ( ($AU:PYC) ) just unveiled an announcement. PYC Therapeutics has highlighted progress in its clinical pipeline with new d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-advances-adoa-drug-pyc-001-with-new-clinical-data-and-ongoing-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-advances-adoa-drug-pyc-001-with-new-clinical-data-and-ongoing-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2621080826","title":"Percheron Therapeutics Launches Discounted Entitlement Offer, Excludes Overseas Holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2621080826","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621080826?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:52","pubTimestamp":1774302768,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics ( ($AU:PER) ) has shared an announcement. Percheron Therapeutics has launched a non-renounceable pro-rata entitlement offer,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/percheron-therapeutics-launches-discounted-entitlement-offer-excludes-overseas-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/percheron-therapeutics-launches-discounted-entitlement-offer-excludes-overseas-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2621743038","title":"Outlook Therapeutics Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2621743038","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621743038?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:30","pubTimestamp":1774301400,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., March  23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260887/0/en/Outlook-Therapeutics-Announces-Proposed-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2621087470","title":"Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087470","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087470?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:30","pubTimestamp":1774301400,"startTime":"0","endTime":"0","summary":"CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS. SYDNEY, March 24, 2026 /PRNewswire/ -- Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, today announced dosing of the first participant in its Phase 1b KOANEWA trial evaluating CTx1000, an investigational genetic medicine targeting pathological forms of the TDP-43 protein in people with amyotrophic lateral sclerosis , also known as motor neuron disease . The study is being conducted at the Neurology Department of Macquarie University Hospital in Sydney, Australia.Dr Kathryn Sunn, Chief Executive Officer at Celosia Therapeutics, said: \"ALS is a progressive and ultimately fatal neurodegenerative disease with limited therapeutic options. The initiation of dosing in the KOANEWA study marks an important milestone for Celosia and, most importantly, for the ALS community. Treating the first patient begins the clinical evaluation of this genetic ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/celosia-therapeutics-announces-first-patient-dosed-in-phase-1b-clinical-trial-of-ctx1000-in-amyotrophic-lateral-sclerosis-302721818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","BK4139","LENZ","BK7055","MND.AU"],"gpt_icon":0},{"id":"2621082934","title":"Context Therapeutics FY Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2621082934","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621082934?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:52","pubTimestamp":1774299120,"startTime":"0","endTime":"0","summary":"Context Therapeutics  reported a FY net loss of $0.38 per diluted share late Monday, narrowing from a loss of $0.46 a year earlier.Analysts polled by FactSet expected a loss of $0.35.The company ended the year with $94.4 million in cash and equivalents. It expects this will be sufficient to fund operations into mid-2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","CNTX","BK4139","LENZ"],"gpt_icon":0},{"id":"2621223082","title":"Context Therapeutics Highlights Evolving T Cell Engager Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2621223082","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621223082?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:49","pubTimestamp":1774298978,"startTime":"0","endTime":"0","summary":"Context Therapeutics ( ($CNTX) ) just unveiled an update. On March 23, 2026, Context Therapeutics Inc. updated its corporate presentation for inves...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-highlights-evolving-t-cell-engager-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-highlights-evolving-t-cell-engager-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","CNTX","BK4139","BK4007"],"gpt_icon":0},{"id":"2621822950","title":"Intensity Therapeutics Expands ATM Equity Offering Capacity","url":"https://stock-news.laohu8.com/highlight/detail?id=2621822950","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621822950?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:43","pubTimestamp":1774298594,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics, Inc. ( ($INTS) ) has issued an update. On March 23, 2026, Intensity Therapeutics, Inc. increased the capacity of its existi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/intensity-therapeutics-expands-atm-equity-offering-capacity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/intensity-therapeutics-expands-atm-equity-offering-capacity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4539","BK4139","BK4007","EQR","LENZ","BK4215","BK4585"],"gpt_icon":0},{"id":"2621804082","title":"Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2621804082","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621804082?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:32","pubTimestamp":1774297920,"startTime":"0","endTime":"0","summary":"LENZ Therapeutics (NASDAQ:LENZ) to release Q4 earnings on 3/24. Analysts expect loss of 90 cents/share. Stock gained 5% on Monday. Analyst ratings and accuracy rates available on Benzinga.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/23/Analysts-Compare-Overvaluation-To-Previo.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/23/Analysts-Compare-Overvaluation-To-Previo.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51420066/top-wall-street-forecasters-revamp-lenz-therapeutics-expectations-ahead-of-q4-earnings","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51420066/top-wall-street-forecasters-revamp-lenz-therapeutics-expectations-ahead-of-q4-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LENZ"],"gpt_icon":0},{"id":"2621084103","title":"Top News Today/Canada: Bank of Canada to Lose Two Members of Rate-Setting Governing Council","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084103","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084103?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:30","pubTimestamp":1774297800,"startTime":"0","endTime":"0","summary":"The Bank of Canada said that two members of its rate-setting governing council are departing, and it intends to fill the vacancies internally.The central bank said that Deputy Governor Rhys Mendes would leave on April 10, to relocate to Toronto with his family. He was responsible for the central bank's analysis of international economic developments.Deputy Governor Sharon Kozicki intends to retire on July 15, following a two-decade career at Canada's central bank. She was responsible for overseeing analysis of domestic economic developments.BOC Speech Takes on Heightened Importance Amid Rapid Turn in Rate Expectations. LaGuardia Airport Reopens Hours After Deadly Runway Collision. New York City's LaGuardia Airport was closed Monday after a passenger jet collided with an emergency vehicle on the runway, killing two pilots and injuring dozens of other people.The two pilots of the Air Canada Express plane were killed in the crash shortly before midnight Sunday, and a further 41 people, in","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","PAYS","KBH","TIL","BK4104","NKTX","ATOS","CNXC","GUTS","BK4007","BZAI","LU2125910336.SGD","BK4141","BK4187","ECTM","BK4505","BK4198","BK4023","LU2089985449.USD","BK4588","PVL","SMTI","AIRJ","SFD","ACHV","BRZE","INTZ","LU1923621640.USD","AIR","BK4139","IE0009354923.USD","BK4082","BK4539","KZR","LU2125910179.SGD","BK4213","IE00B7SZL793.SGD","CNM","LU2065169927.USD","COLFF","MXCT","ABSI","LENZ","SFES","LU2065171402.SGD","EPSN","IE00B19Z4B17.USD","BK4135","BK4572","BK4161"],"gpt_icon":0},{"id":"2621084505","title":"Small U.S. Stocks Move Upward; Damora Therapeutics Top Leaders","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084505","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084505?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:21","pubTimestamp":1774297260,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies increased Monday, as the Russell 2000 Index increased 2.3%, and the S&P Small Cap 600 Index was up 2.1%.Among companies with a market value of $1 billion to $6.7 billion, Damora Therapeutics Inc. was the best performer during the session, surging 27%, followed by Apogee Therapeutics Inc., which jumped 20%. AXT Inc. shares jumped 19%, Sigma Lithium Corp. jumped 14%, and shares of Red Cat Holdings Inc. jumped 14%.Braiin Ltd. was the biggest laggard, dropping 12%, followed by shares of SolarEdge Technologies Inc., which dropped 9.7%. Shares of Enphase Energy Inc. dropped 7.6%, Zenas BioPharma Inc. shares tumbled 7.5%, and Liberty Energy Inc. tumbled 7.4%.Major U.S. stock indexes rose Monday with the Nasdaq Composite Index rising 1.4%. Meanwhile, the S&P 500 Index increased 1.1%, and the Dow Jones Industrial Average gained 1.4%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4007","LENZ"],"gpt_icon":0},{"id":"2621308457","title":"Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621308457","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621308457?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:20","pubTimestamp":1774297237,"startTime":"0","endTime":"0","summary":"Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.10) by 34.62 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51419676/context-therapeutics-q4-eps-0-14-misses-0-10-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2621084339","title":"Press Release: Context Therapeutics Reports Full Year 2025 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084339","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084339?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:16","pubTimestamp":1774296960,"startTime":"0","endTime":"0","summary":"Phase 1a interim data for ongoing trial of CTIM-76  expected in June 2026. Phase 1a interim data for ongoing trial of CT-95  expected in September 2026. Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027. PHILADELPHIA, March 23, 2026  -- Context Therapeutics Inc.  , a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights.\"We believe 2025 was a year of significant progress for Context as we advanced our pipeline of T cell-engaging bispecific antibodies for solid tumors. We are on track to provide Phase 1a interim data for our CTIM-76 trial in June 2026. We are also continuing dose escalation for CT-95 toward target dose levels and expect to provide Phase 1a interim data for this trial in September 2026. Looking ahead, we anticipate dosing the first","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2621083422","title":"Quince Therapeutics options imply 68.7% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2621083422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621083422?lang=en_us&edition=fundamental","pubTime":"2026-03-24 01:35","pubTimestamp":1774287347,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in Quince Therapeutics (QNCX) is normal with calls leading puts 17:1. Implied volatility suggests the market is anticip...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-options-imply-68-7-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-options-imply-68-7-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2621707990","title":"Pelthos Therapeutics Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2621707990","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621707990?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:15","pubTimestamp":1774278922,"startTime":"0","endTime":"0","summary":"11:13 EDT Pelthos Therapeutics (PTHS) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pelthos-therapeutics-inc-trading-resumes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pelthos-therapeutics-inc-trading-resumes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTHS","LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2621704699","title":"Qyuns Therapeutics Invests RMB100 Million in Low-Risk Wealth Management Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2621704699","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621704699?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:09","pubTimestamp":1774274972,"startTime":"0","endTime":"0","summary":"An announcement from Qyuns Therapeutics Co., Ltd. Class H ( ($HK:2509) ) is now available. Qyuns Therapeutics has subscribed to a principal-guarant...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/qyuns-therapeutics-invests-rmb100-million-in-low-risk-wealth-management-product?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/qyuns-therapeutics-invests-rmb100-million-in-low-risk-wealth-management-product?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4539","LENZ"],"gpt_icon":0},{"id":"2621706522","title":"Tempest Therapeutics Announces Private Placement Financing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706522","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706522?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:47","pubTimestamp":1774270077,"startTime":"0","endTime":"0","summary":"An update from Tempest Therapeutics ( ($TPST) ) is now available. Tempest Therapeutics entered into a securities purchase agreement on March 20, 20...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tempest-therapeutics-announces-private-placement-financing-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tempest-therapeutics-announces-private-placement-financing-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2621706487","title":"Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706487","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706487?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:45","pubTimestamp":1774269900,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS Formal centralized and independent analysis of the clinical response data from the ACCENT trial has been undertaken and updated analysis provided to the CompanyThe data confirm that five (5","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260403/0/en/Amplia-Therapeutics-Reports-Four-Additional-Complete-Responses-and-Improved-Overall-Survival-Data-in-Accent-Pancreatic-Cancer-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","INNMF","BK4007","ORR","PFS","PR","BK4211","BK4161","BK4097","BK4539","LENZ","BK4213","BK4195","BK4139","OS"],"gpt_icon":0},{"id":"2621703222","title":"Damora Therapeutics appoints Jennifer Jarrett as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703222","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703222?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:15","pubTimestamp":1774268141,"startTime":"0","endTime":"0","summary":"Damora Therapeutics (DMRA) announced that its board of directors has appointed Jennifer Jarrett as president and CEO, effective March 30. Jarrett w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/damora-therapeutics-appoints-jennifer-jarrett-as-ceo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/damora-therapeutics-appoints-jennifer-jarrett-as-ceo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4539","LENZ","DMRA"],"gpt_icon":0},{"id":"2621708772","title":"Press Release: Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2621708772","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621708772?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:00","pubTimestamp":1774267200,"startTime":"0","endTime":"0","summary":"-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance --. -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors --. -- Peter Harwin named Chairman of the Board of Directors --. BOSTON, March 23, 2026  -- Damora Therapeutics, Inc. , a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that its Board of Directors has appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Ms. Jarrett will also serve on the company's Board of Directors.\"We are excited to welcome Jen to Damora as we accelerate our efforts to bring innovative medicines to patients with mutant calreticulin -driven myeloproliferative neoplasm ,\" said Peter Harwin, Chairman of the Board of Directors of Damora Therapeutics. \"With a track record of success in oncology drug development and building and leading high-growth companies, Jen brings a unique se","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4022","BK4007","DMRA","BK4139","R","BK4539","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":6,"totalSize":260,"code":"91000000","status":"200"}]}}